Pharma Blog Watch
The
Enzi-Kennedy FDA Bill (DrugWonks.com)
In his entry, blogger Robert
Goldberg expresses concerns about a New York Times article in which Gardiner
Harris "depicted the Enzi-Kennedy FDA bill as a throwback to slow paper gathering
approaches to drug safety without regard to 21st century science or proposals
to accelerate a response to the more expensive and prevalent 'side effects' of
having a disease like Alzheimer's without effective treatments." Goldberg
writes about the bill, the Critical Path Initiative, and the way in which Harris'
article overlooked some key components of the issue.
Speeding
Up the Drug Approval Process? (Eye on FDA)
Will the drug approval process
be expedited? In his entry, blogger Mark Senak discusses recent congressional
action regarding this issue.